Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PReCedeNT Trial: Phase III Randomised Controlled Open Label Trial of Lutetium 177 PRRT Plus Chemotherapy Versus PRRT Aalone in FDG Avid Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors

NCT07185672 is registered in ClinicalTrials.gov with Tata Memorial Hospital as lead sponsor.

NCT NCT07185672
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07185672 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PReCedeNT Trial: Phase III Randomised Controlled Open Label Trial of Lutetium 177 PRRT Plus Chemotherapy Versus PRRT Aalone in FDG Avid Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors
Lead sponsor
Tata Memorial Hospital
Phase
Phase 3
Overall status
Recruiting
Start date
August 7, 2019
Completion date
August 7, 2027
Enrollment
162 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

neuroendocrine gastroenteropancreatic tumour, neuroendocrine neoplasia's (nens), neuroendocrine tumor gep grade 1-3